171 related articles for article (PubMed ID: 15929168)
1. Anti-gastric cancer active immunity induced by FasL/B7-1 gene-modified tumor cells.
Zheng SY; Li DC; Zhang ZD; Zhao J; Ge JF
World J Gastroenterol; 2005 Jun; 11(21):3204-11. PubMed ID: 15929168
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated FasL gene transfer into human gastric carcinoma.
Zheng SY; Li DC; Zhang ZD; Zhao J; Ge JF
World J Gastroenterol; 2005 Jun; 11(22):3446-50. PubMed ID: 15948252
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B7.1 expression and IFN-gamma secretion.
Kim TS; Chung SW; Kim SH; Kang SN; Kang BY
Int J Cancer; 2000 Aug; 87(3):427-33. PubMed ID: 10897050
[TBL] [Abstract][Full Text] [Related]
4. Expression of B7 costimulation molecules by colorectal cancer cells reducestumorigenicity and induces anti-tumor immunity.
Hu JY; Wang S; Zhu JG; Zhou GH; Sun QB
World J Gastroenterol; 1999 Apr; 5(2):147-151. PubMed ID: 11819415
[TBL] [Abstract][Full Text] [Related]
5. Purification of antigenic peptide from murine hepatoma cells recognized by Class-I major histocompatibility complex molecule-restricted cytotoxic T-lymphocytes induced with B7-1-gene-transfected hepatoma cells.
Nakatsuka K; Sugiyama H; Nakagawa Y; Takahashi H
J Hepatol; 1999 Jun; 30(6):1119-29. PubMed ID: 10406192
[TBL] [Abstract][Full Text] [Related]
6. Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 genes co-transfected liver cancer cell vaccines.
Ge NL; Ye SL; Zheng N; Sun RX; Liu YK; Tang ZY
World J Gastroenterol; 2003 Oct; 9(10):2182-5. PubMed ID: 14562374
[TBL] [Abstract][Full Text] [Related]
7. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L
Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939
[TBL] [Abstract][Full Text] [Related]
8. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
Kim TS; Lee BC; Kim E; Cho D; Cohen EP
Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
[TBL] [Abstract][Full Text] [Related]
9. Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.
Lee SH; Bar-Haim E; Goldberger O; Reich-Zeliger S; Vadai E; Tzehoval E; Eisenbach L
Immunol Lett; 2004 Feb; 91(2-3):119-26. PubMed ID: 15019279
[TBL] [Abstract][Full Text] [Related]
10. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street.
Zeytun A; Hassuneh M; Nagarkatti M; Nagarkatti PS
Blood; 1997 Sep; 90(5):1952-9. PubMed ID: 9292529
[TBL] [Abstract][Full Text] [Related]
11. Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model.
Raes G; Van Ginderachter J; Liu YQ; Brys L; Thielemans K; De Baetselier P; Geldhof A
Cancer Immunol Immunother; 1998 Jan; 45(5):257-65. PubMed ID: 9439649
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral vector-mediated gene therapy in the mouse lung: no role of Fas-Fas ligand interactions for elimination of transgene expression in bronchioepithelial cells.
Chirmule N; Moffett J; Dhagat P; Tazelaar J; Wilson JM
Hum Gene Ther; 1999 Nov; 10(17):2839-46. PubMed ID: 10584929
[TBL] [Abstract][Full Text] [Related]
13. [Anti-tumor immune response to cervical carcinoma induced by costimulatory molecule B7 gene in mice].
Tao G; Zou H; Hu J
Zhonghua Fu Chan Ke Za Zhi; 2001 Feb; 36(2):111-4. PubMed ID: 11783347
[TBL] [Abstract][Full Text] [Related]
14. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
Yang G; Hellström KE; Hellström I; Chen L
J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
[TBL] [Abstract][Full Text] [Related]
15. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis.
Daniel PT; Kroidl A; Cayeux S; Bargou R; Blankenstein T; Dörken B
J Immunol; 1997 Oct; 159(8):3808-15. PubMed ID: 9378968
[TBL] [Abstract][Full Text] [Related]
16. Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.
Li JH; Rosen D; Sondel P; Berke G
Immunology; 2002 Mar; 105(3):267-77. PubMed ID: 11918688
[TBL] [Abstract][Full Text] [Related]
17. Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer.
Zheng HC; Sun JM; Wei ZL; Yang XF; Zhang YC; Xin Y
World J Gastroenterol; 2003 Jul; 9(7):1415-20. PubMed ID: 12854132
[TBL] [Abstract][Full Text] [Related]
18. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy.
Kanwar JR; Shen WP; Kanwar RK; Berg RW; Krissansen GW
J Natl Cancer Inst; 2001 Oct; 93(20):1541-52. PubMed ID: 11604477
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells reconstituted with a human heparanase gene induce potent cytotoxic T-cell responses against gastric tumor cells in vitro.
Cai YG; Fang DC; Chen L; Tang XD; Chen T; Yu ST; Luo YH; Xiong Z; Wang DX; Yang SM
Tumour Biol; 2007; 28(4):238-46. PubMed ID: 17717429
[TBL] [Abstract][Full Text] [Related]
20. Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma.
Leong CC; Marley JV; Loh S; Milech N; Robinson BW; Garlepp MJ
Int J Cancer; 1997 May; 71(3):476-82. PubMed ID: 9139887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
